Business Context and Reporting Period
This Form 8-K Current Report is filed by 180 Life Sciences Corp. (not Forum Markets Inc.) for the reporting period ending June 12, 2025, with additional events reported through June 17, 2025. The filing primarily addresses corporate governance changes, including the resignation of a director, the adoption of a new equity incentive plan, and significant executive compensation adjustments.
Key Financial Metrics and Compensation
The filing does not report operational financial metrics such as revenue, profit, cash flow, or debt levels. Financial data is limited to specific compensation and equity transactions:
- Director Severance: Total payment of $98,333.33 to former director Jay Goodman ($7,583.33 accrued fees, $36,750 future fees, and $54,000 additional payment).
- CEO Compensation: Annual fee of $240,000 (increasing to $350,000 upon a material transaction of $100M+); potential annual bonus of 50% to 100% of the fee.
- Equity Grants:
- CEO Blair Jordan: 410,000 stock options and 179,646 restricted shares.
- CAO Eric R. Van Lent: 25,000 stock options and 8,763 restricted shares.
- Non-Executive Directors: Combined 530,000 stock options and 230,036 restricted shares.
- Stock Price: Exercise price for new options set at $0.9290 per share (closing price on June 17, 2025).
Material Changes Versus Prior Period
- Board Composition: Jay Goodman resigned as a director effective June 13, 2025. His 65,000 unvested shares were forfeited and canceled.
- Equity Plan Adoption: The Board adopted the 2025 Option Incentive Plan, reserving 1,000,000 shares for awards. This plan requires shareholder approval within 12 months to remain valid.
- Executive Contract Terms: The CEO's consulting agreement was amended to extend the term through December 31, 2027 (previously 2026) and introduced a fee increase trigger tied to material transactions.
- Vesting Acceleration: The Board accelerated the vesting of 160,000 restricted shares for the CEO and 65,000 shares for each of three non-executive directors, making them fully vested as of June 17, 2025.
Guidance, Outlook, Risks, and Unusual Items
Management Commentary and Outlook: The filing contains no operational guidance or financial outlook. The focus is strictly on governance and compensation alignment.
Risks and Contingencies:
- Shareholder Approval Risk: The 2025 Option Incentive Plan is subject to unwinding and cancellation of granted options if shareholder approval is not obtained within 12 months.
- Severance Obligations: The amended CEO agreement includes significant "change in control" or "good reason" termination provisions, including immediate vesting of all equity and severance equal to two times the annual fee plus bonuses.
- Forfeiture: The resignation of Mr. Goodman resulted in the immediate forfeiture of his unvested equity.
Investor Verification Checklist
- Verify the status of the 2025 Option Incentive Plan shareholder vote and the timeline for approval.
- Confirm the total number of shares authorized under the new 2025 Plan versus the existing 2022 Plan to assess dilution impact.
- Review the specific performance metrics for the CEO's discretionary bonus, which can range from 50% to 100% of the base fee.
- Monitor the company's cash position to ensure it can meet the immediate severance obligations to Mr. Goodman and potential future CEO severance liabilities.
- Check for any subsequent filings regarding the resignation of Mr. Goodman to ensure no undisclosed disagreements exist.